Home > Newsletters > Drug Industry Daily > FDA Highlights Cardio Risks With Novo Insulin Drugs, Analysts Eye Challenging Approval
Drug Industry Daily
Nov. 7, 2012 | Vol. 11 No. 219
FDA Highlights Cardio Risks With Novo Insulin Drugs, Analysts Eye Challenging Approval
Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg appear to be associated with an increase in cardiovascular risk, FDA reviewers said in briefing documents leading up to a Thursday advisory panel meeting.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.